Recovery from rituximab-associated persistent hypogammaglobulinaemia in children with nephrotic syndrome

There are limited data on the long-term outcomes and risk factors for non-recovery after development of rituximab (RTX)-associated persistent hypogammaglobulinaemia among children with idiopathic nephrotic syndrome (NS).